
Back
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Retina specialists come together to share key insights from multiple patient cases, highlighting how novel therapies like faricimab and aflibercept 8 mg have improved durability and patient outcomes in neovascular AMD, DME, and RVO.
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome
4
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
5



